Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 10:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,788 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: MAJOR DEPRESSIVE DISORDER Clear all
Completed Phase 2 Interventional Results available

Reducing Internalized Stigma in People With Serious Mental Illness

NCT01259427
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression With Psychotic Features
Interventions
Ending Self Stigma (ESS), Health and Wellness Group
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Perry Point, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Oct 15, 2026, 10:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder

NCT00025974
View directory record Official record
Conditions
Panic Disorder, Posttraumatic Stress Disorder, Major Depressive Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Not applicable Interventional

Triple Chronotherapy in Adolescents

NCT03679962
View directory record Official record
Conditions
Depressive Disorder, Major, Bipolar Depression, Suicidal Ideation
Interventions
Triple Chronotherapy, Treatment as Usual
Behavioral
Lead sponsor
Billings Clinic
Other
Eligibility
12 Years to 17 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Billings, Montana
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care for Depression

NCT01407094
View directory record Official record
Conditions
Depression
Interventions
Sertraline, Placebo, BupropionXL
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
296 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 15, 2026, 10:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder

NCT03336918
View directory record Official record
Conditions
Bipolar Disorder, Bipolar I Depression, Bipolar II Depression, Bipolar Depression, Depression, Major Depressive Episode
Interventions
Lithium
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 2 Interventional

Mechanistic Evaluation of Response in TRD (MERIT)

NCT04608396
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

NCT03051256
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
REL-1017, Placebo
Drug
Lead sponsor
Relmada Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Little Rock, Arkansas • Garden Grove, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT03002077
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
128
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 2 Interventional Results available

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

NCT02285504
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-547
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 4 Interventional Results available

Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

NCT00696293
View directory record Official record
Conditions
Major Depressive Disorder, Back Pain, Aged
Interventions
Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 15, 2026, 10:07 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dopamine Neurotransmission in Major Depression

NCT01659814
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Belmont, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 15, 2026, 10:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Development of Attentional Biases for Affective Cues in Infants of Mothers With Depression

NCT06835855
View directory record Official record
Conditions
Depression - Major Depressive Disorder
Interventions
Passive Viewing Task, Interaction Task
Other
Lead sponsor
Binghamton University
Other
Eligibility
6 Months and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Binghamton, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 15, 2026, 10:07 PM EDT
Not listed Phase 2 Interventional

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

NCT04593563
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Maryland Oncology Hematology, PA
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Not applicable Interventional Results available

Social Reward and Its Effect on Brain Functions in Psychotherapies for Mid- and Late-Life Depression

NCT04487730
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
"Engage & Connect" Psychotherapy, Symptom Review and Psychoeducation (SRP)
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

A Long-Term Safety Study of ALKS 5461

NCT02141399
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALKS 5461
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
123
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 105 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 15, 2026, 10:07 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations

NCT04296604
View directory record Official record
Conditions
Traumatic Brain Injury, Major Depressive Disorder, Bipolar Disorder, Schizophrenia, Attention Deficit Hyperactivity Disorder, Borderline Personality Disorder, Substance Use Disorders
Interventions
Transcranial Direct Current Stimulation
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

NCT02943577
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Imperial, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Not applicable Interventional Results available

rTMS for PTSD Comorbid With Major Depressive Disorder

NCT02273063
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Major Depressive Disorder, Transcranial Magnetic Stimulation, Repetitive
Interventions
Transcranial Magnetic Stimulation (TMS)
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 3 Interventional Results available

Opiate Suicide Study in Patients With Major Depression

NCT04116528
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 4 Interventional Results available

Study of Brain Response to Emotional Pictures Using a Magnetic Resonance Imaging (fMRI) While on Escitalopram

NCT00707863
View directory record Official record
Conditions
Major Depression
Interventions
Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 15, 2026, 10:07 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Not applicable Interventional Results available

Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders

NCT01947647
View directory record Official record
Conditions
Major Depressive Disorder, Persistent Depressive Disorder, Posttraumatic Stress Disorder, Panic Disorder, Social Phobia, Specific Phobia, Generalized Anxiety Disorder, Obsessive Compulsive Disorder
Interventions
Transdiagnostic Behavior Therapy, Behavioral Activation Therapy
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 15, 2026, 10:07 PM EDT
Recruiting Not applicable Interventional

Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness

NCT05491538
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Stress Disorder, Post-Traumatic
Interventions
Social Cognition and Interaction Training-Work Edition (SCIT-WE)
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 15, 2026, 10:07 PM EDT
Completed Phase 2 Interventional

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

NCT06785012
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-89495120, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
44
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 15, 2026, 10:07 PM EDT